Cargando…

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review

In addition to facilitating healthcare delivery planning, reliable information about prognosis is essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This review aimed to evaluate the prognosis of patients with IPF without anti-fibrotic therapy. We included all co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khor, Yet H., Ng, Yvonne, Barnes, Hayley, Goh, Nicole S.L., McDonald, Christine F., Holland, Anne E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488716/ https://www.ncbi.nlm.nih.gov/pubmed/32759374 http://dx.doi.org/10.1183/16000617.0158-2019

Ejemplares similares

Cough in Idiopathic Pulmonary Fibrosis
por: Mann, Jennifer, et al.
Publicado: (2021)

Inhaled Nitric Oxide for Fibrotic Interstitial Lung Disease: A Step Forward
por: Khor, Yet H., et al.
Publicado: (2022)

Developing a self-management package for pulmonary fibrosis: an international Delphi study
por: Lee, Joanna Y.T., et al.
Publicado: (2022)

Understanding patient experience of chronic cough in interstitial lung disease
por: Mann, Jennifer M.V., et al.
Publicado: (2023)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume
por: Du, Kaifeng, et al.
Publicado: (2022)

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study
por: Wu, Wen-Jui, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
por: Fujimoto, Hajime, et al.
Publicado: (2016)

A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease
por: Khor, Yet H., et al.
Publicado: (2021)

Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial
por: Holland, Anne E, et al.
Publicado: (2020)

Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns
por: Khor, Yet H., et al.
Publicado: (2019)

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
por: Takei, Reoto, et al.
Publicado: (2023)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
por: Roach, Katy M., et al.
Publicado: (2018)

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis
por: Fernández Fabrellas, Estrella, et al.
Publicado: (2018)

Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone
por: Jiang, Chun-guo, et al.
Publicado: (2019)

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions
por: Khor, Yet H., et al.
Publicado: (2022)

Self-management interventions for people with pulmonary fibrosis: a scoping review
por: Lee, Joanna Y.T., et al.
Publicado: (2023)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore
por: Kam, Michelle Li Wei, et al.
Publicado: (2022)

Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment
por: Kaur, Amarpreet, et al.
Publicado: (2017)

Editorial: Idiopathic pulmonary fibrosis: epidemiology, prognosis and treatment
por: Caminati, Antonella, et al.
Publicado: (2023)

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Antigen avoidance and environmental inhalation challenge for successful diagnosis of fibrotic hypersensitivity pneumonitis mimicking idiopathic pulmonary fibrosis
por: Ito, Yasuhiro, et al.
Publicado: (2022)

Bronchoalveolar Lavage Cell Count and Lymphocytosis Are the Important Discriminators between Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Sobiecka, Małgorzata, et al.
Publicado: (2023)

The In Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis
por: Liu, Tianju, et al.
Publicado: (2014)

The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review
por: Lee, Joanna Y.T., et al.
Publicado: (2020)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis
por: Bahmer, Thomas, et al.
Publicado: (2017)

Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis
por: Cheng, Xiaoyun, et al.
Publicado: (2023)

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
por: Shioya, Makoto, et al.
Publicado: (2018)

Identification of Pro-Fibrotic Macrophage Populations by Single-Cell Transcriptomic Analysis in West Highland White Terriers Affected With Canine Idiopathic Pulmonary Fibrosis
por: Fastrès, Aline, et al.
Publicado: (2020)

Dyspnoea with progressive “idiopathic” pulmonary fibrosis
por: Puri, Chahat, et al.
Publicado: (2021)

A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mk9lcsof4tljb7pibn3esni3t0